Domo signs strategic collaboration agreement with AWS for AI solutions
Acurx Pharmaceuticals LLC (ACXP) stock has plummeted to a 52-week low, trading at $0.43, with InvestingPro data showing the stock is now 87% below its 52-week high of $3.33. While technical indicators suggest oversold conditions, the micro-cap company, valued at just $7.5 million, faces a challenging period marked by a significant downturn in its market valuation. Over the past year, ACXP has seen its stock price erode, culminating in an alarming 1-year change of -84.44%. This steep decline has raised concerns among investors and analysts who are closely monitoring the company’s performance and potential recovery plans. According to InvestingPro analysis, the company maintains a healthy current ratio of 1.8 and holds more cash than debt, though it remains unprofitable with weak gross margins. The current price level reflects investor sentiment and market conditions that have weighed heavily on the pharmaceutical firm’s stock, signaling a critical juncture for Acurx Pharmaceuticals in navigating its future business strategy. For comprehensive analysis of ACXP and 1,400+ other stocks, explore the detailed Pro Research Reports available on InvestingPro.
In other recent news, Acurx Pharmaceuticals has made significant strides in its clinical and patent endeavors. The company announced that its lead antibiotic candidate, ibezapolstat, has shown promising results in selectively targeting harmful bacteria while preserving beneficial gut microbiota. This development comes as Acurx prepares to advance ibezapolstat into international Phase 3 clinical trials for treating Clostridioides difficile Infection (CDI), following positive feedback from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The Phase 3 trials will compare ibezapolstat to the standard-of-care vancomycin, focusing on clinical cure rates and reducing recurrence, with prior Phase 2 trials reporting a 96% clinical cure rate.
Additionally, Acurx Pharmaceuticals secured a new patent from the Japanese Patent Office for its DNA Polymerase IIIC Inhibitors, which are essential for its ACX-375C program targeting Gram-positive bacterial infections. This patent is part of the company’s strategy to build a robust global patent portfolio. The company has already obtained patents in the United States and Israel and is pursuing more in other countries. Executive Chairman Robert J. DeLuccia highlighted the patent’s importance in advancing Acurx’s AI-supported drug discovery platform for second-generation DNA pol IIIC inhibitors. These recent developments underscore Acurx’s ongoing efforts to address difficult-to-treat bacterial infections and expand its antibiotic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.